Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof
CA 2391944 A1 · Owner: Lajolla Pharmaceutical Company · Inventors: Linnik, Matthew D.; Mcneeley, Patricia A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides methods identifying individuals suitable for treatment for lupus and methods of monitoring treatment based on measuring antibody , affinities as well as of treating lupus based on measuring antibody affinities. The treatment entails administration of a conjugate comprising a non-immunogenic valency platform molecule and at least two double stranded DNA epitopes, such as DNA molecules, which bind to anti-DNA antibodies from the patient.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 28, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 28, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 28, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.